334 related articles for article (PubMed ID: 9923450)
1. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
[TBL] [Abstract][Full Text] [Related]
2. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
[TBL] [Abstract][Full Text] [Related]
3. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
4. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.
Ulich TR; del Castillo J; Senaldi G; Kinstler O; Yin S; Kaufman S; Tarpley J; Choi E; Kirley T; Hunt P; Sheridan WP
Blood; 1996 Jun; 87(12):5006-15. PubMed ID: 8652813
[TBL] [Abstract][Full Text] [Related]
5. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
7. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
8. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
[TBL] [Abstract][Full Text] [Related]
10. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
11. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
[TBL] [Abstract][Full Text] [Related]
13. The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia.
Adams JA; Liu Yin JA; Brereton ML; Briggs M; Burgess R; Hyde K
Br J Haematol; 1997 Oct; 99(1):139-46. PubMed ID: 9359514
[TBL] [Abstract][Full Text] [Related]
14. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.
Harker LA; Hunt P; Marzec UM; Kelly AB; Tomer A; Hanson SR; Stead RB
Blood; 1996 Mar; 87(5):1833-44. PubMed ID: 8634430
[TBL] [Abstract][Full Text] [Related]
15. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor.
Shibuya K; Kuwaki T; Tahara E; Yuki C; Akahori H; Kato T; Miyazaki H
Exp Hematol; 2002 Oct; 30(10):1185-92. PubMed ID: 12384150
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.
Ulich TR; del Castillo J; Yin S; Swift S; Padilla D; Senaldi G; Bennett L; Shutter J; Bogenberger J; Sun D
Blood; 1995 Aug; 86(3):971-6. PubMed ID: 7620187
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
20. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]